Table 6.
Clinical features of OSAS in patients with epilepsy
| OSAS (n: 19) | no OSAS (n: 24) | p-value | OR | CI | p-value | |
|---|---|---|---|---|---|---|
| Age | 42,8 (±11,3) | 34,7 (±11,24) | 0,0239 | 1,1 | (1,0–1,1) | 0,03 |
| BMI | 28,2 (± 4,86) | 27,88 (±5,46) | ns | 1,0 | (0,9–1,1) | ns |
| Age at epilepsy onset (yrs) | 28,5 (± 16,5) | 20,9 (±11,09) | ns | 1,0 | (0,9–1,0) | ns |
| Duration of epilepsy (yrs) | 14,3 (±15,8) | 14 (±10,3) | ns | 1,0 | (0,9–1,0) | ns |
| Males (%) | 89,4% (17/19) | 62,5% (15/24) | 0,04 | 5,1 | (0,9–27,4) | 0,06 |
| Focal epilepsy (%) | 84,2% (16/19) | 58,3% (14/24) | 0,06 | 3,8 | (0,9–16,7) | 0,07 |
| Seizures during sleep (%) | 42,1% (8/19) | 54,1% (13/24) | ns | 0,6 | (0,2–2,1) | ns |
| Secondarily generalized seizures (%) | 73,6% (14/19) | 37,5% (9/24) | 0,02 | 4,7 | (1,2–17,4) | 0,02 |
| Bitherapy | 21% (4/19) | 33,3% (8/24) | ns | 0,5 | (0,1–2,1) | ns |
| Drug-resistance | 31,5% (6/19) | 33,3% (8/24) | ns | 0,9 | (0,2–3,3) | ns |
OSAS, obstructive sleep apnoea syndrome; OR, Odd ratio; CI, confidence interval; BMI, Body Mass Index.